The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: An open-label, one-sequence, three-period, three-treatment crossover study

Clinical Therapeutics

Volumn 31, Issue 12, 2009, Pages 3009-3020

  Shin, Kwang Hee ^a   Kim, Bo Hyung ^a   Kim, Tae Eun ^a   Kim, Jae Woo ^a   Yi, SoJeong ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

CYP3A4; drug drug interaction; ketoconazole; mirodenafil; rifampicin

Indexed keywords

KETOCONAZOLE; MIRODENAFIL; MVIX; PHOSPHODIESTERASE V INHIBITOR; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; EPISTAXIS; FLU LIKE SYNDROME; HEAT SENSATION; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; RHINORRHEA; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; KOREA; MALE; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINONES; RIFAMPIN; SULFONAMIDES; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 74549134772     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.12.012     Document Type: Article

References (39)

1. Paick J.S., Choi H.K., Kim S.C., et al. Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: A multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian J Androl. 10 (2008) 791-798
2. Paick J.S., Ahn T.Y., Choi H.K., et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med. 5 (2008) 2672-2680
3. Hatzimouratidis K., and Hatzichristou D.G. Looking to the future for erectile dysfunction therapies. Drugs. 68 (2008) 231-250
4. Lee H.S., Park E.J., Ji H.Y., et al. Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica. 38 (2008) 21-33
5. Coleman M.D. Human Drug Metabolism: An Introduction (2005), John Wiley, Chichester, UK; Hoboken, NJ
6. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet. 38 (2000) 111-180
7. Niemi M., Kivistö K.T., Diczfalusy U., et al. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics. 16 (2006) 565-568
8. Yoo H.H., Kim N.S., Im G.J., and Kim D.H. Pharmacokinetics and tissue distribution of a novel PDE5 inhibitor, SK-3530, in rats. Acta Pharmacol Sin. 28 (2007) 1247-1253
9. Ek M., Soderdahl T., Kuppers-Munther B., et al. Expression of drug metabolizing enzymes in hepatocytelike cells derived from human embryonic stem cells. Biochem Pharmacol. 74 (2007) 496-503
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharma- ceuticals for Human Use (ICH). ICH harmonised tripartite guide- line: Guideline for good clinical practice E6(R1). http://www.ich.org/LOB/media/MEDIA482.pdf Accessed June 19, 2009
11. World Medical Association (WMA). World Medical Association Declaration of Helsinki - Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html Accessed June 19, 2009
12. Shin B.S., Hu S.K., Kim J., et al. Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d] pyrimidin-4-one (SK3530) in human plasma: Application to a clinical pharmacokinetic study. J Pharm BiomedAnal. 45 (2007) 176-184
13. Oh J.G., Jang W.J., and Chi S.C. Validation of a HPLC method for the quantification and purity determination of SK3530 in drug substance and tablet. J Pharm Biomed Anal. 43 (2007) 1179-1184
14. Drug interaction studies-study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4079B1_04_Topic2-TabA.pdf Accessed June 19, 2009
15. Ring B.J., Patterson B.E., Mitchell M.I., et al. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: Studies in vitro and in vivo. Clin Pharmacol Ther 77 (2005) 63-75
16. Muirhead G.J., Wulff M.B., Fielding A., et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 50 (2000) 99-107
17. Mehrotra N., Gupta M., Kovar A., and Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 19 (2007) 253-264
18. Ji H.Y., Lee H.W., Kim H.H., et al. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica. 34 (2004) 973-982
19. Gupta M., Kovar A., and Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 45 (2005) 987-1003
20. Jetter A., Kinzig-Schippers M., Walchner-Bonjean M., et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther. 71 (2002) 21-29
21. Christ B., Brockmeier D., Hauck E.W., and Friemann S. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. Urology. 58 (2001) 589-593
22. Wilner K., Laboy L., and LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol. 53 Suppl 1 (2002) 31S-36S
23. Center for Drug Evaluation and Reearch. NDA 021368 Cialis (Tadalafil) Tablet. Clinical Pharmacology/ Biopharmaceutics Review (2003), US Dept of Health and Human Services, Rockville, Md. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-368_Cialis_BioPharmr_P1.pdf Accessed June 19, 2009
24. Wacher V.J., Wu C.Y., and Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 13 (1995) 129-134
25. Wandel C., Kim R.B., Kajiji S., et al. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res. 59 (1999) 3944-3948
26. Zhang Y., Guo X., Lin E.T., and Benet L.Z. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos. 26 (1998) 360-366
27. Wang E.J., Lew K., Casciano C.N., et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 46 (2002) 160-165
28. Matheny C.J., Ali R.Y., Yang X., and Pollack G.M. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos. 32 (2004) 1008-1014
29. Greiner B., Eichelbaum M., Fritz P., et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin [published correction appears in J Clin Invest. 2002;110:571]. J Clin Invest. 104 (1999) 147-153
30. Schuetz E.G., Beck W.T., and Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 49 (1996) 311-318
31. Kim K.A., Park P.W., Liu K.H., et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol. 48 (2008) 66-72
32. Ji H.Y., Shim H.J., Yoo M., et al. Transport of a new erectogenic udenafil in Caco-2 cells. Arch Pharm Res. 30 (2007) 1168-1173
33. Jian-Wei I.S., Shon J., and Shin J. Characterization of efflux transport of PDE5 inhibitors, sildenafil, vardenafil, and udenafil [PII-40]. Presented at: The 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. March 18-21 (2009), National Harbor, Maryland
34. Kim R.B., Wandel C., Leake B., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 16 (1999) 408-414
35. Kruuse C., Thomsen L.L., Birk S., and Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 126 (2003) 241-247
36. Gibbs M.A., Baillie M.T., Shen D.D., et al. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharm Res. 17 (2000) 299-305
37. Madsen J.L. Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci. 37 (1992) 1548-1553
38. Niemi M., Backman J.T., Fromm M.F., et al. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin Pharmacokinet. 42 (2003) 819-850
39. Ku H.Y., Ahn H.J., Seo K.A., et al. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. DrugMetab Dispos. 36 (2008) 986-990